Evidence map›Paper›PMID 30004908›Full record

ReviewCurrent opinion in urology2018

Update on epidemiologic considerations and treatment trends in testicular cancer.

Solomon L Woldu, Aditya Bagrodia

Abstract readReview
In one paragraph

Review in Current opinion in urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Solomon L WolduUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.
Aditya Bagrodia
Aditya Birla (India) · INThe University of Texas Southwestern Medical Center · US

Funding

Physician Scientist Oncology Training ProgramT32CA136515 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2009 to 2018
$2.2M
NCI NIH HHS T32 CA136515
6 · The paper itself

Abstract

purpose of reviewWe aim to give an overview of the epidemiology and treatment trends of testicular germ cell tumors (TGCTs), with an emphasis on recent trends. RECENT

findingsThe incidence of TGCT appears to be increasing, particularly in developed countries, although the reasons are not well understood. There is evidence of racial differences in predisposition to TGCT, with white men having highest risk and men of African or Asian descent having lower risk. In the United States, the incidence of TGCT among Hispanics appears to be rising most quickly. A recent genomic analysis indicates there is no highly penetrant major TGCT susceptibility gene. Incorporation of multidisciplinary care has led to excellent long-term cure rates; however, access to care and insurance remains barriers in young men. Recent treatment trends have centered on maximizing oncologic outcomes while minimizing long-term morbidity. SUMMARY: Emerging population-level data provide critical insight into the evolving demographics of TGCT, which may allow for elucidation of biologic and environmental determinants of TGCT. Further, identification of socioeconomic barriers to excellent clinical outcomes will allow for targeted interventions to patients with unique demographic and socioeconomic considerations. Treatment trend analyses suggest that the field is moving toward minimizing treatment-related morbidity.

Indexed as

Chemotherapy, AdjuvantEthnicityGenetic Predisposition to DiseaseHealth Services AccessibilityHumansIncidenceMaleNeoplasms, Germ Cell and EmbryonalOrchiectomyPopulation GrowthRadiotherapy, AdjuvantTesticular NeoplasmsUnited States

Identifiers

PMID30004908
PMCPMC6134403
OpenAlexW2884357314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.